Varespladib is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2). The molecule acts as an anti-inflammatory agent by disrupting the first step of the arachidonic acid pathway of inflammation. From 2006 to 2012, varespladib was under active investigation by Anthera Pharmaceuticals as a potential therapy for several inflammatory diseases, including acute coronary syndrome and acute chest syndrome. The trial was halted in March 2012 due to inadequate efficacy.

CAS：172733-42-5
中文别名：
英文别名：UNII-F6M52CDT0W;Varespladib sodium;
分子式：C21H19N2NaO5
分子量：402.376
精确质量：402.119
Psa：114.45
Logp：1.749

UNII：F6M52CDT0W

储存条件：2-8°C，密封，干燥